{
  "id": 11180422,
  "title": "H.C. Wainwright cuts ProQR stock price target on execution risks",
  "url": "https://urgent.news/2026/10/01/h-c-wainwright-cuts-proqr-stock-price-target-on-execution-risks",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-01T11:44:51.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-cuts-proqr-stock-price-target-on-execution-risks-93CH-4927228"
  },
  "original_language": "en",
  "account": "H.C. Wainwright has reduced its price target on ProQR Therapeutics N.V. (PRQR) stock to $8.00 from $12.00, retaining a Buy rating. Analyst Andrew Fein cited execution risks and regulatory uncertainties as the reasons for the reduction. The company's stock is currently trading at $1.66, down 18% year-to-date and 23% over the past year. Despite this, InvestingPro analysis suggests that ProQR is currently undervalued. The company has more cash than debt and maintains liquid assets exceeding short-term obligations, but it is also rapidly using up its cash reserves—an important factor for investors in pre-revenue biotech firms. ProQR is set to host a research and development day focusing on NTCP modulation in biliary atresia, led by Prof. Gideon Hirschfield. The company's AX-0810 drug showed clean safety with no serious adverse events, no pruritus, and no bilirubin change, while demonstrating dose-dependent engagement across three biomarkers and an eight-week half-life. H.C. Wainwright believes that advancing AX-0810 and AX-0811 into biliary atresia will validate ProQR's platform clinically, supported by human genetic data and the bilirubin hypothesis in biliary atresia. ProQR has also received a Buy rating from BofA Securities with a $8.00 price target, emphasizing the significance of AX-0810, the first human validation of ProQR's Axiomer technology.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "H.C. Wainwright reiterates Syndax stock Buy rating at $38 target",
        "url": "https://urgent.news/2026/10/01/h-c-wainwright-reiterates-syndax-stock-buy-rating-at-38-target",
        "published": "2026-10-01T11:44:45.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}